Clinical Trials on Glycogen Storage Disease Type II in Australia

Total 2994 results

Genzyme, a Sanofi Company

Completed

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase Deficiency

United States, Canada, Australia
Genzyme, a Sanofi Company

Completed

Late-Onset Treatment Study Extension Protocol

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)

United States, France, Canada, Netherlands, Australia
Medical University of Vienna

Recruiting

Novel Metabolic Muscular Biomarkers in Pompe Disease - a Non-invasive Magnetic Resonance Exploratory Pilot Study. (POMPE)

Pompe Disease | McArdle Disease

Austria
Genzyme, a Sanofi Company

Completed

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET)

Glycogen Storage Disease Type II;Pompe's Disease

Czechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
BioMarin Pharmaceutical

Terminated

Extension Study for Patients Who Have Participated in a BMN 701 Study

Pompe Disease

United States, United Kingdom, Australia, France, Germany, New Zealand
Amicus Therapeutics

Active, not recruiting

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Pompe Disease

United States, Netherlands, United Kingdom, Australia, Germany, New Zealand
BioMarin Pharmaceutical

Completed

Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

Pompe Disease

United States, United Kingdom, France, Australia, Germany
Amicus Therapeutics

Recruiting

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Pompe Disease (Late-onset)

United States, Taiwan, Japan, Australia, Canada
BioMarin Pharmaceutical

Terminated

A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease

Late-onset Pompe Patients Untreated or Treated With rhGAA

Spain, Slovenia, Serbia, Korea, Republic of, Greece, Australia, Singapore, Brazil, Canada, Taiwan, Ireland, Poland, Romania
Amicus Therapeutics

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Pompe Disease (Late-onset)

United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
Amicus Therapeutics

Terminated

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Late-onset Pompe Disease

United States, Canada, Australia, Belgium
Genzyme, a Sanofi Company

Recruiting

Pompe Disease Registry Protocol

Glycogen Storage Disease Type II | Pompe Disease

Hungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaborators

Recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab. (TOP-FLOR)

Follicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IV

Australia
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
LipimetiX Development, LLC

Completed

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

Hypercholesterolemia | Hyperlipoproteinemia Type II

Australia
University of Adelaide
Royal Adelaide Hospital

Completed

Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air (HOTAIR4)

Insulin Resistance | Diabetes Mellitus, Type II

Australia
Medical University of Vienna

Unknown

Surgical Treatment Of Complex Regional Pain Syndrome Type II (CRPS II)

CRPS Type II

Austria
DyaMX Inc.

Active, not recruiting

Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes (REGENT-1)

Type 2 Diabetes

Australia
The University of Western Australia
National Health and Medical Research Council, Australia

Unknown

Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils (FIFH)

Familial Hypercholesterolaemia | Hypertriglyceridaemia

Australia
Arbeitsgemeinschaft medikamentoese Tumortherapie
Amgen

Terminated

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

KRAS Wild Type | Resectable Type II Gastric Adenocarcinoma

Austria
Medical University of Vienna

Completed

Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements

Diabetes Mellitus Type II

Austria
Medical University of Graz

Completed

Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders (CARDIONOR)

Diabetes Mellitus, Type II

Austria
Melanoma and Skin Cancer Trials Limited

Recruiting

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)

Neuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine Skin

Australia, New Zealand
Arrowhead Pharmaceuticals

Completed

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

Dyslipidemias | Hypertriglyceridemia | Familial Hypercholesterolemia

Australia, New Zealand
Queensland Centre for Gynaecological Cancer
Royal Brisbane and Women's Hospital

Not yet recruiting

NODE (groiN ultrasOunD cancEr) (NODE)

Ultrasound Therapy; Complications | Lymph Node Metastasis | Groin Node | Vulvar Cancer Stage Ib | Vulvar Cancer Stage II

Australia
Immutep Australia Pty. Ltd.

Completed

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel)

Stage IV Melanoma | Stage III Melanoma

Australia
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
Evaxion Biotech A/S
Merck Sharp & Dohme LLC

Recruiting

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Australia
Medical University of Vienna

Unknown

Soy Food Intervention Trial (SOYFIT)

Familial Hypercholesterolemia

Austria
Medical University of Vienna

Unknown

Effect of Rapeseed Oil and Sunflower Oil

Familial Hypercholesterolemia

Austria
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) (Gateway)

Homozygous Familial Hypercholesterolemia

Australia, Canada, United States, South Africa
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing... and other conditions

United States, Canada, Australia
University of Adelaide
Salk Institute for Biological Studies; University of South Australia

Completed

Time RestrIcted Feeding For Improving Diabetes Risk (TRIFFID) (TRIFFID)

Obesity | Type2 Diabetes

Australia
Austrian Breast & Colorectal Cancer Study Group

Completed

Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B

Colon Cancer Stage II

Austria
Austrian Academic Institute for Clinical Nutrition
Medical University of Vienna

Completed

Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia (SOYFIT)

Heterozygous Familial Hypercholesterolemia

Austria
Regeneron Pharmaceuticals

Completed

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Australia, Austria, Netherlands, Taiwan, Ukraine
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

Refractory Childhood Hodgkin Lymphoma | Ann Arbor Stage I Childhood Hodgkin Lymphoma | Ann Arbor Stage II Childhood Hodgkin Lymphoma | Ann Arbor Stage III Childhood Hodgkin Lymphoma | Ann Arbor Stage IV Childhood Hodgkin Lymphoma

United States, Canada, Australia, Switzerland
Goethe University

Active, not recruiting

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE)

Anal Cancer | Anal Carcinoma | Anal Cancer Stage III | Anal Cancer Stage II

Germany, Switzerland, Austria
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
Melbourne Health
Sanofi

Withdrawn

Complement Activation in the Lysosomal Storage Disorders (CATALYST)

Lysosomal Storage Diseases | Fabry Disease | Niemann-Pick Disease, Type C | Gaucher Disease

Australia
Medical University of Vienna

Unknown

The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)

CKD II-III

Austria
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Ann Arbor Stage I Childhood Hodgkin Lymphoma | Ann Arbor Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma

United States, Canada, Australia, New Zealand, Puerto Rico, Israel
Melanoma and Skin Cancer Trials Limited
Bristol-Myers Squibb; Amgen; Peter MacCallum Cancer Centre, Australia

Active, not recruiting

Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (CHARLI)

Melanoma | Melanoma Stage Iv | Melanoma Stage Iii

Australia
ISU Abxis Co., Ltd.

Completed

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Gaucher Disease

Australia
Melanoma and Skin Cancer Trials Limited
Norfolk and Norwich University Hospitals NHS Foundation Trust; Canadian Cancer... and other collaborators

Recruiting

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (MelMarT-II)

Cutaneous Melanoma, Stage II

United States, Canada, United Kingdom, Australia, Italy, Sweden, Netherlands, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Adult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditions

United States, Canada, Australia, New Zealand

Clinical Trials on Glycogen Storage Disease Type II in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations